___
PT-141 · Neurological Desire Support

PT-141 in Ann Arbor

PT-141 (bremelanotide) is FDA-approved as Vyleesi® for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is prescribed only after a clinical consultation. Other uses are off-label and are discussed only during a consultation.
PT-141 peptide therapy molecular structure

PT-141

Bremelanotide · Brand Name: Vyleesi®

Mechanism: Melanocortin receptor agonist. FDA-approved as Vyleesi® for HSDD in premenopausal women.

PT-141 acts centrally in the brain rather than on blood flow, engaging pathways involved in sexual desire.

Individual response and administration are determined at consultation.

Pricing for PT-141 (Vyleesi®) is discussed at consultation.

Common side effects and contraindications are reviewed individually at consultation.

FDA status disclosure: PT-141 is FDA-approved as Vyleesi® for HSDD in premenopausal women only. Other uses are off-label and are discussed only during a consultation.

How PT-141 Works

PT-141

Activates the neurological pathway associated with sexual desire. Individual response and administration are discussed at consultation.

PT-141 · Ann Arbor

Desire Isn't Just
Vascular. Treat the
Whole System.

PT-141 is assessed at consultation alongside hormone panels and a complete clinical history, guided by a clinician who understands the vascular, hormonal, and neurological dimensions of desire.

PT-141 · Pricing at consultation

PT-141: Regulatory Status

PT-141 (bremelanotide) is FDA-approved as Vyleesi® for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Arbour Longevity prescribes it only for this FDA-approved indication, after clinical evaluation and informed consent, with a discussion of known risks and contraindications.

Reviewed by Gandhi Bhattarai, FNP-BC, PMHNP-BC, Anti-Aging/Functional Medicine BC — triple board certified nurse practitioner

Last updated: August 2, 2026

This page is provided for educational purposes and is not a substitute for individualized medical advice. Whether a treatment is appropriate for you is determined during consultation.